The present invention relates to method detecting analytes by surface enhanced Raman spectroscopy (SERS), comprising contacting the analytes with at least one analyte binding molecule attached to a metal substrate surface that enhances Raman scattering via a Raman-active molecular linker; and detect
The present invention relates to method detecting analytes by surface enhanced Raman spectroscopy (SERS), comprising contacting the analytes with at least one analyte binding molecule attached to a metal substrate surface that enhances Raman scattering via a Raman-active molecular linker; and detecting a surface enhanced Raman signal from said compound. In a further aspect, this invention relates to a conjugate and a biosensor suitable for the invented SERS-based analyte detection method.
대표청구항▼
1. A method for detecting one or more analytes using surface enhanced Raman spectroscopy (SERS), comprising: contacting the one or more analytes with a conjugate, the conjugate comprising at least one analyte binding molecule attached to a metal substrate surface via a Raman-active molecular linker
1. A method for detecting one or more analytes using surface enhanced Raman spectroscopy (SERS), comprising: contacting the one or more analytes with a conjugate, the conjugate comprising at least one analyte binding molecule attached to a metal substrate surface via a Raman-active molecular linker that enhances Raman scattering of the metal substrate and undergoes a structural change upon an analyte binding event in which the one or more analytes bind to the at least one analyte binding molecule; anddetecting peak shifts in the surface enhanced Raman spectrum from said conjugate as an indication of the analyte binding event, wherein the peak shifts in the surface enhanced Raman spectrum of the conjugate are correlated with amount of the one or more analytes. 2. The method of claim 1, wherein the one or more analytes are selected from the group consisting of proteins, peptides, nucleic acids, carbohydrates, lipids, cells, viruses, small molecules, and haptens. 3. The method of claim 1, wherein the at least one analyte binding molecule specifically binds the one or more analytes. 4. The method of claim 3, wherein the at least one analyte binding molecule is selected from the group consisting of an antibody, an antibody fragment, and antibody-like molecules. 5. The method of claim 3, wherein the at least one analyte binding molecule is a monoclonal or polyclonal antibody. 6. The method of claim 1, wherein the method is a multiplex method for detecting more than one analyte, wherein in the contacting step more than one analyte binding molecule is used. 7. The method of claim 1, wherein the at least one analyte binding molecule is covalently coupled to the Raman-active molecular linker, wherein the Raman-active molecular linker is attached to the substrate surface via covalent interactions. 8. The method of claim 1, wherein the Raman-active molecular linker is selected from the group consisting of 6-Mercaptopurine, 8-Aza-adenine, N-Benzoyladenine, 2-Mercapto-benzimidazole, 4-Amino-pyrazole[3,4-d]pyrimidine, Zeatin, Methylene Blue, 9-Amino-acridine, Ethidium Bromide, Bismarck Brown Y, N-Benzylaminopurine, Thionin acetate, 3,6-Diaminoacridine, 6-Cyanopurine, 4-Amino-5-imidazolecarboxamidehydrochloride, 1,3-Diiminoisoindoline, Rhodamine 6G, Crystal Violet, Basic Fuchsin, Aniline Blue Diammonium salt, N-[(3-(Anilinomethylene)-2-chloro-1-cyclohexen-1-yl)methylene]anilinemonohydrochloride, O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate, 9-Aminofluorene hydrochloride, Basic Blue, 1,8-Diamino-4,5-dihydroxyanthraquinone, Proflavine hemisulfate salt hydrate, 2-Amino-1,1,3-propenetricarbonitrile, Variamine Blue RT salt, 4,5,6-Triaminopyrimidine sulfate salt, 2-Aminobenzothiazole, Melamine, 3-(3-Pyridylmethylamino)Propionitrile, Silver(I) Sulfadiazine, Acriflavine, 4-Amino-6-mercaptopyrazole[3,4-d]pyrimidine, 2-Aminopurine, Adenine Thiol FAD Fluoroadenine, 4-Amino-6-mercapyopyrazole[3,4-d]pyrimidine, Rhodamine 110, Adenine, 5-Amino-2-mercaptobenzimidazole, Acridine Orange Hydrochloride, Cresyl Violate Acetate, Acriflavine Neutral, Dimidium Bromide, 5,10,15,20-Tetrakis(N-methyl-4-pyridinio)porphyrin Tetra(p-toluenesulfonate), 5,10,15,20-Tetrakis(4-trimethylaminophenyl)porphyrin Tetra(p-toluenesulfonate), 3,5-Diaminoacridine Hydrochloride, Propidium Iodide (3,8-diamino-5-(3-diethylaminopropyl)-6-phenylphenanthridinium iodidemethiodide), Trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium iodide, and 4-((4-(dimethylamino)phenyl)azo)benzoic acid, succinimidyl ester or derivatives thereof. 9. The method of claim 8, wherein the Raman-active molecular linker is a thiol-group containing compound. 10. The method of claim 9, wherein the Raman-active molecular linker is 6-Mercaptopurine. 11. The method of claim 1, wherein the at least one analyte binding molecule is covalently coupled to the Raman-active molecular linker by amide bond formation. 12. The method of claim 11, wherein 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide is used as a coupling agent. 13. The method of claim 1, wherein the substrate is a nanoparticle.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (3)
Hanson, Douglas Charles; Neveu, Mark Joseph; Mueller, Eileen Elliott; Hanke, Jeffrey Herbert; Gilman, Steven Christopher; Davis, C. Geoffrey; Corvalan, Jose Ramon, Human monoclonal antibodies to CTLA-4.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.